作者: Nancy U Lin , Christoph Thomssen , Fatima Cardoso , David Cameron , Tanja Cufer
DOI: 10.1016/J.BREAST.2013.03.006
关键词:
摘要: In clinical practice, the surveillance and follow-up of patients with breast cancer (BC) is quite variable. At 7th European Breast Cancer Conference, ESO-MBC Task Force convened a series lectures, followed by open debate, on use physical examination, imaging, laboratory tests in early-stage BC, for restaging evaluations among MBC. Based available data, recommends against intensive, routine radiologic or blood-based (with exception mammography) BC. As systemic therapies MBC continue to improve, this question might be re-visited context carefully controlled trial specific BC subtypes. For MBC, response therapy should generally assessed 2-3 months after initiation treatment, thereafter every 2-4 endocrine cycles chemotherapy, depending dynamics disease, location extent metastatic involvement, type treatment. Additional testing performed irrespective planned intervals if progression disease suspected (e.g. case symptoms). Use tumor markers not recommended patients, but may helpful monitoring disease. However, change alone used decision-making. Moving forward, enhanced efforts document quality life over time made order more fully evaluate risk/benefit ratio options.